menu
    • menu
    [{"orgOrder":0,"company":"T-Cure Bioscience","sponsor":"Immunotech Biopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"HERV-E TCR Transduced CD8+\/CD34+ Enriched T Cell","moa":"HERV-E","graph1":"Oncology","graph2":"Phase I","graph3":"T-Cure Bioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"T-Cure Bioscience \/ Immunotech Biopharm","highestDevelopmentStatusID":"6","companyTruncated":"T-Cure Bioscience \/ Immunotech Biopharm"},{"orgOrder":0,"company":"T-Cure Bioscience","sponsor":"Atlas Antibodies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"820TCR","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"T-Cure Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"T-Cure Bioscience \/ Atlas Antibodies","highestDevelopmentStatusID":"4","companyTruncated":"T-Cure Bioscience \/ Atlas Antibodies"}]

    Find Clinical Drug Pipeline Developments & Deals by T-Cure Bioscience

    Menu

    T-Cure Bioscience

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            T-Cure Bioscience

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            T-Cure Bioscience

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 820TCR

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Atlas Antibodies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            T-Cure Bioscience, Inc. and Atlas Antibodies AB Enter a Collaboration Agreement for the Development, Manufactu...

                            Details : Atlas Antibodies AB will provide all manufacturing and product supply for KK-LC-1 mAb for the companion diagnostic. T-Cure is developing 820TCR targeting KK-LC-1 for gastric, triple negative breast cancer, cervical, lung and other KK-LC-1 positive cancer...

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 10, 2021

                            Lead Product(s) : 820TCR

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Atlas Antibodies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            T-Cure Bioscience

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed

                            T-Cure Bioscience

                            U.S.A arrow
                            ChemOutsourcing
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HERV-E TCR Transduced CD8+/CD34+ Enriched T Cell

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Immunotech Biopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            T-Cure Bioscience and Immunotech Biopharm Ltd Announce License Agreement for Novel HERV-E T Cell Receptor Ther...

                            Details : Immunotech Biopharm Ltd will have rights to develop and commercialize 800TCR, a HERV-E targeting T cell receptor (TCR) therapy for the treatment of kidney cancer, in China.

                            Product Name : Undisclosed

                            Product Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            January 20, 2021

                            Lead Product(s) : HERV-E TCR Transduced CD8+/CD34+ Enriched T Cell

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Immunotech Biopharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth